Localized Non-Small Cell Lung Cancer 2024 UPDATE

Dr. Jennifer Marks, a thoracic oncologist at Dana-Farber Cancer Institute and Harvard medical instructor, dives deep into localized non-small cell lung cancer (NSCLC). She discusses the latest on staging using the TNM classification and treatment strategies for both resectable and unresectable cases. Key highlights include the impact of the PACIFIC trial and innovative adjuvant chemotherapy approaches. Dr. Marks emphasizes the integration of molecular testing and multidisciplinary care to enhance patient outcomes, shedding light on evolving standards in oncology.